The preclinical data using this antibody-based therapy were promising as combination of treatment of SS1P with radiation, taxol or gemcitabine resulted in enhanced antitumor activity against mesothelin-expressing tumour xenografts [29,30,31]. The gene discussed is MSLN; the disease is neoplasm.